Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials

Cancer Treatment Reviews

Volumn 39, Issue 1, 2013, Pages 44-50

  Brollo, Janaina ^a   Curigliano, Giuseppe ^a   Disalvatore, Davide ^a   Marrone, Bianca Fontana ^b   Criscitiello, Carmen ^a   Bagnardi, Vincenzo ^a,c   Kneubil, Maximiliano Cassilha ^a   Fumagalli, Luca ^a   Locatelli, Marzia ^a   Manunta, Silvia ^a   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Adjuvant treatment; Breast cancer; Elderly patients; Geriatric oncology; Systematic review; Trastuzumab

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ACUTE DISEASE; BREAST CANCER; CANCER ADJUVANT THERAPY; CHRONIC DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; GERIATRIC PATIENT; HEALTH CARE QUALITY; HEART DEATH; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MULTIPLE CYCLE TREATMENT; NUTRITIONAL STATUS; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GERIATRICS; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2;

EID: 84869092866     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.03.009     Document Type: Review

References (42)

1. Ghandhi S., Verma S. Early breast cancer in the older woman. The Oncologist 2011, 16(4):479-485.
2. Wildiers H., Kunkler I., Biganzoli L., et al. Management of breast cancer in elderly individuals: recommendations of the international society of geriatric oncology. Lancet Oncol 2007, 8(12):1101-1115.
3. Ferlay J, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No5, version 2.0. Lyon: IARC Press GLOBOCAN; 2004.
4. Diab S.G., Elledge R.M., Clark G.M. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000, 92(7):550-556.
5. Gennari R., Curigliano G., Rotmensz N., et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. Cancer 2004, 101(6):1302-1310.
6. Muss H. Coming of age: breast cancer in seniors. Oncologist 2011, 16(suppl1):79-87.
7. Kimmick G. Adjuvant chemotherapy for breast cancer in older women: emerging evidence to aid in decision making. Curr Treat Options Oncol 2011, 10.1007/s11864-011-0159-
8. Wildiers H. Challenges in treating older cancer patients: breast cancer. Ann Oncol 2008, vii(suppl7):99-103.
9. Hurria A., Lachs M.S., Cohen H.J., et al. Geriatric assessment for oncologists: rationale and future directions. Crit Rev Oncol Hematol 2006, 59(3):211-217.
10. Hurria A., Wong F., Pal S., et al. Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists. Oncologist 2009, 14(9):883-890.
11. Crivellari D., Aapro M., Leonard R., et al. Breast cancer in the elderly. J Clin Oncol 2007, 25(14):1882-1890.
12. Piccard-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2 - positive breast cancer. N Engl J Med 2005, 353(16):1659-1672.
13. Gianni L., Gelber R., Azambuja E., et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomized controlled trial. Lancet Oncol 2011, 12(3):236-244.
14. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684.
15. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analyses of data from N9831 and NSABP B-31. J Clin Oncol 2011; published on line july 18, 2011 as http://dx.doi.org/10.1200/JCO.2011.35.0868.
16. Joensuu H., Kellokumpu-Lehtinen P., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354(8):809-820.
17. Spielmann M., Roché H., Delozier T., et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009, 27(36):6129-6134.
18. Slamon D., Eiermann W., Robert N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365(14):1273-1283.
19. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987, 9:1-30.
20. Freeman M.F., Tukey J.W. Transformations related to the angular and the square root. Ann Math Stat 1950, 21:607-611.
21. Miller J J. The inverse of the Freeman-Tukey double arcsine transformation. Am Stat 1978, 32:138.
22. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
23. Suter T.M., Procter M., van Veldhuisen D.J., et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007, 25(25):3859-3865.
24. Tan-chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node positive, human epidermal growth factor receptor 2- over expressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23(31):7811-7819.
25. Perez E.A., Suman V.J., Davidson N.E., et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008, 26(8):1231-1238.
26. Surveillance Epidemiology and End Results Cancer Statistics Review. Accessed June 21, 2011, at http://seer.cancer.gov/csr/1975_2005/results_merged/sect_04_breast.pdf.
27. Early Breast Cancer Trialists' Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717.
28. Berry D.A., Cronin K.A., Plevritis S.K., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353(17):1784-1792.
29. Christman K., Muss H.B., Case L.D., Stanley V. Chemotherapy of metastatic breast cancer in the elderly: the Piedmont Oncology Association experience. JAMA 1992, 268(1):57-62.
30. Ibrahim N.K., Frye D.K., Buzdar A.U., Walters R.S., Hortobagyi G.N. Doxorubicin based chemotherapy in elderly patients with metastatic breast cancer: tolerance and outcome. Arch Intern Med 1996, 156(8):882-888.
31. Muss H.B., Berry D.A., Cirrincione C., et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the cancer and leukemia group B Experience. J Clin Oncol 2007, 25(24):3699-3704.
32. Muss H.B., Woolf S., Berry D., et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005, 293(9):1073-1081.
33. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A., Albain K.S. Underrepresentation of 65years of age or older in cancer-treatment trials. N Engl J Med 1999, 341(27):2061-2067.
34. Fentiman I.S., Van Zijl J., Karydas I., et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10850 comparing modified radical mastectomy with tumorectomy plus tamoxifen. Eur J Cancer 2003, 39(3):300-308.
35. Fentiman I.S., Christiaens M.R., Paridaens R., et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer 2003, 39(3):309-316.
36. Yanick R., Ries L.G., Yates J.W. Breast cancer in aging women. A population-based study of contrasts in stage, surgery, and survival. Cancer 1989, 63(5):976-981.
37. Crivellari D. Results of adjuvant treatments in breast cancer patients over 70 years old: the IBCSG experience. International Breast Cancer Study Group. Tumori 2002, 88(1 Suppl 1):S81-2.
38. de Azambuja E., Bedard P.L., Suter T., Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies - what have we learned so far?. Targ Oncol 2009, 4(2):77-88.
39. Procter M., Suter T.M., de Azambumja E., et al. Longer-terrm assessment of trastuzumab-related cardiac adverse events is the Herceptin Adjuvant (HERA) trial. J Clin Oncol 2010, 28(20):3422-3428.
40. Hurria A., Togawa K., Supriya M.G., et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011, 29:3457-3465.
41. Serrano C, Cortés J, De Mattos-Arruda L, et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 2011 Aug 9. [Epub ahead of print].
42. Pinder M.C., Duan Z., Goodwin J.S., et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007, 25:3808-3815.